187 related articles for article (PubMed ID: 32421389)
21. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
[TBL] [Abstract][Full Text] [Related]
22. Technical considerations for circulating tumor DNA detection in oncology.
Franczak C; Filhine-Tresarrieu P; Gilson P; Merlin JL; Au L; Harlé A
Expert Rev Mol Diagn; 2019 Feb; 19(2):121-135. PubMed ID: 30648442
[TBL] [Abstract][Full Text] [Related]
23. Role of liquid biopsies in colorectal cancer.
Wills B; Gorse E; Lee V
Curr Probl Cancer; 2018 Nov; 42(6):593-600. PubMed ID: 30268335
[TBL] [Abstract][Full Text] [Related]
24. Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges.
Rodda AE; Parker BJ; Spencer A; Corrie SR
ACS Sens; 2018 Mar; 3(3):540-560. PubMed ID: 29441780
[TBL] [Abstract][Full Text] [Related]
25. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
Shi Y; Su H; Song Y; Jiang W; Sun X; Qian W; Zhang W; Gao Y; Jin Z; Zhou J; Jin C; Zou L; Qiu L; Li W; Yang J; Hou M; Xiong Y; Zhou H; Du X; Wang X; Peng B
EBioMedicine; 2020 Apr; 54():102731. PubMed ID: 32304999
[TBL] [Abstract][Full Text] [Related]
26. Molecular Monitoring of Cell-Free Circulating Tumor DNA in Non-Hodgkin Lymphoma.
Melani C; Roschewski M
Oncology (Williston Park); 2016 Aug; 30(8):731-8, 744. PubMed ID: 27539624
[TBL] [Abstract][Full Text] [Related]
27. The future of cell-free DNA testing to guide therapeutic decisions in B-cell lymphomas.
Condoluci A; Rossi D
Curr Opin Hematol; 2019 Jul; 26(4):281-287. PubMed ID: 31082825
[TBL] [Abstract][Full Text] [Related]
28. Circulating Tumor DNA in Lymphoma: Principles and Future Directions.
Roschewski M; Rossi D; Kurtz DM; Alizadeh AA; Wilson WH
Blood Cancer Discov; 2022 Jan; 3(1):5-15. PubMed ID: 35015693
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
30. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas.
Bobillo S; Crespo M; Escudero L; Mayor R; Raheja P; Carpio C; Rubio-Perez C; Tazón-Vega B; Palacio C; Carabia J; Jiménez I; Nieto JC; Montoro J; Martínez-Ricarte F; Castellvi J; Simó M; Puigdefàbregas L; Abrisqueta P; Bosch F; Seoane J
Haematologica; 2021 Feb; 106(2):513-521. PubMed ID: 32079701
[TBL] [Abstract][Full Text] [Related]
31. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
32. Liquid biopsy in breast cancer: A comprehensive review.
Alimirzaie S; Bagherzadeh M; Akbari MR
Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
[TBL] [Abstract][Full Text] [Related]
33. The potential of ctDNA analysis in breast cancer.
Tzanikou E; Lianidou E
Crit Rev Clin Lab Sci; 2020 Jan; 57(1):54-72. PubMed ID: 31674269
[TBL] [Abstract][Full Text] [Related]
34. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
35. Prognostication with circulating tumor DNA: is it ready for prime time?
Kurtz DM
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):47-52. PubMed ID: 31808836
[TBL] [Abstract][Full Text] [Related]
36. [Current situation and prospect of breast cancer liquid biopsy].
Zhou B; Xin L; Xu L; Ye JM; Liu YH
Zhonghua Wai Ke Za Zhi; 2018 Feb; 56(2):106-109. PubMed ID: 29397622
[TBL] [Abstract][Full Text] [Related]
37. Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma.
Fu H; Shen J; Zhou H; Zhang F; Li H; Ma Z; Huang W; Chen L; Chen Y; Liu T
Eur J Haematol; 2022 Apr; 108(4):298-309. PubMed ID: 34997652
[TBL] [Abstract][Full Text] [Related]
38. Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?
Lenaerts L; Tuveri S; Jatsenko T; Amant F; Vermeesch JR
Acta Clin Belg; 2020 Feb; 75(1):9-18. PubMed ID: 31578135
[No Abstract] [Full Text] [Related]
39. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.
Meriranta L; Alkodsi A; Pasanen A; Lepistö M; Mapar P; Blaker YN; Jørgensen J; Karjalainen-Lindsberg ML; Fiskvik I; Mikalsen LTG; Autio M; Björkholm M; Jerkeman M; Fluge Ø; Brown P; Jyrkkiö S; Holte H; Pitkänen E; Ellonen P; Leppä S
Blood; 2022 Mar; 139(12):1863-1877. PubMed ID: 34932792
[TBL] [Abstract][Full Text] [Related]
40. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
Chen X; Wang L; Lou J
Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
